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Abstract
Introduction Several theoretical accounts of the role of
dopamine suggest that dopamine has an influence on the
processing of affective stimuli. There is some indirect
evidence for this from studies showing an association
between the treatment with dopaminergic agents and self-
reported affect.
Materials and methods We addressed this issue directly by
examining the electrophysiological correlates of affective
picture processing during a single-dose treatment with a
dopamine D2 agonist (bromocriptine), a dopamine D2
antagonist (haloperidol), and a placebo. We compared early
and late event-related brain potentials (ERPs) that have been
associated with affective processing in the three medication
treatment conditions in a randomized double-blind crossover
design amongst healthy males. In each treatment condition,
subjects attentively watched neutral, pleasant, and unpleas-
ant pictures while ERPs were recorded.
Results Results indicate that neither bromocriptine nor
haloperidol has a selective effect on electrophysiological
indices of affective processing. In concordance with this, no
effects of dopaminergic modulation on self-reported posi-
tive or negative affect was observed. In contrast, bromo-
criptine decreased overall processing of all stimulus
categories regardless of their affective content.
Discussion The results indicate that dopaminergic D2
receptors do not seem to play a crucial role in the selective
processing of affective visual stimuli.
Keywords Dopamine . ERP. Haloperidol . Bromocriptine .
Affective processing
Introduction
Dopaminergic neurotransmission has been suggested to be
involved in several functions of the brain that are associated
with reward, such as the experience of rewarding feelings
(Wise and Bozarth 1985), reward-related reversal learning
(Mitul et al. 2001), motivational aspects of reward (Robinson
and Berridge 1993), and reward processing (Day and Carelli
2007). In addition, dopamine neurons mediate reward signals
in appetitive learning of visual stimuli (Schultz 1997).
Recently, Robbins and Everitt (2007) stated that “the role
of enhanced DA activity is to increase responsivity to cues
paired with reinforcement”. In addition to these functions,
there are suggestions that dopamine is involved in the
regulation of affect (Saeedi et al. 2006). Most studies
addressing the role of dopamine in affect-regulation have
been carried out among animals. Few studies address the
role of dopamine in affect among humans. Studies among
Parkinson’s disease patients, whose mesencephalic dopa-
mine activity is decreased, show that dopamine is able to
modulate emotional responding (Wieser et al. 2006). In
addition, it has been demonstrated that dopamine is also
involved in the perceptual processing of fearful stimuli in
Parkinson disease patients (Tessitore et al. 2002). No studies
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are known which address whether dopamine is able to
modulate the processing of affective stimuli in normal
subjects. However, there are some indirect suggestions
pointing towards a role of dopamine in affective processing.
Takahashi et al. (2005) showed among healthy volunteers
watching unpleasant pictures that the dopamine D2 receptor
antagonist sultopride decreased responses in the limbic areas
(amygdala, hippocampus, anterior cingulate), which are
associated with affective processing. In contrast, they found
that sultopride produced greater activations in the cortical
areas (frontal, temporal, and parietal), and no effect of
sultopride on self-reported affect was found, suggesting a
complex role of dopamine in affective processing.
With regard to psychopathology, what several theoretical
accounts of psychopathological behavior have in common is
that they state that dopamine may have a function in signaling
relevant or salient information (Franken 2003; Kapur 2003;
Robinson and Berridge 1993) and suggest that dopamine is
involved in the processing of information having motiva-
tional relevance. In concordance with this notion, Franken
et al. (2004) showed that the attention-capturing properties
of heroin-related stimuli in heroin-dependent patients were
decreased as result of treatment with the dopamine
antagonist haloperidol. Indirect evidence that dopamine is
involved in the processing of affective information comes
from a study of Taylor et al. (2005) among schizophrenics.
They found that structures with extensive dopaminergic
innervations, such as the ventral striatum, show blunted
responses to emotional salience in schizophrenics.
In addition, several theories suggest that dopamine is
involved in the experience of self-reported positive affect
(Ashby et al. 1999; Burgdorf and Panksepp 2006). In
concordance with these notions, several studies examining
the effects of dopamine-antagonists, in particular D2
antagonists such as haloperidol, report a blunting of the
self-reported affective response (e.g., Mizrahi et al. 2007).
In contrast, dopamine agonists result in self-reported
enhanced mood (Saeedi et al. 2006; Willner et al. 2005).
In the present study, we use event-related potentials
(ERPs) to investigate the processing of affective stimuli, in
particular reward-associated stimuli, in humans. ERPs
measured during the perception of pictures are known to
vary with their affective contents (Cacioppo et al. 1994;
Cuthbert et al. 2000; Keil et al. 2001; Schupp et al. 2000).
Affective pictures, both pleasant and unpleasant, elicit
larger late positive potentials (LPP; starting 300–400 ms
after picture onset until picture offset) than neutral pictures.
LPPs capture controlled processes and are generated by a
diffuse network including anterior areas such as the
orbitofrontal cortex (Rule et al. 2002; Vuilleumier 2005)
and higher order visual areas such as parietal and occipito-
temporal regions (Keil et al. 2002). In addition to these late
effects, the viewing of affective pictures results in reduced
ERP amplitudes in the early time window (150–300) as
compared to neutral stimuli (Codispoti et al. 2007; Schupp
et al. 2006). This early ERP effect is sometimes referred to
as the early posterior negativity (EPN; Schupp et al.
2003b). The EPN, which is associated with the perceptual
encoding of emotional material, may reflect the call for
resources in the capacity-limited second stage of processing
(Codispoti et al. 2007; Schupp et al. 2006) and is generated
in the visual occipito-temporal regions (Schupp et al. 2006).
In passive viewing contexts such as in the present study,
the EPN and LPP modulation by affective stimuli are similar
in respect to the fact that they are both pronounced for high
arousing pleasant and unpleasant stimuli (Schupp et al.
2006). However, it seems that the LPP, in contrast to the
EPN, is enlarged when allocating top-down attentional
resources to emotion, suggesting that the EPN is relatively
insensitive to voluntarily attentional processes. Previous
studies show that similar designs that study the electrophys-
iological activation to affective pictures are able to measure
the modulation of affective processing by psychopharmaco-
logical agents (Franken et al. 2007; Kemp et al. 2004).
This study will investigate whether a D2 agonist or a D2
antagonist can modulate the electrophysiological response
to affective pictures. Decrease in dopaminergic activity will
be induced by a single oral dose of 2 mg haloperidol. This
dose does not produce serious side effects (Franken et al.
2004; Kahkonen et al. 2001), and 2 mg was shown to be
able to induce modulation of the processing of neutral and
rewarding information (Franken et al. 2004; Kahkonen et al.
2001). Increase in dopamine will be induced by a single oral
dose of 2.5 mg bromocriptine. Generally spoken, there are
several indications that bromocriptine can modulate the
response towards rewarding stimuli (Kirsch et al. 2006).
As dopamine is associated with an enhanced signalling
of reward-related stimuli, it was expected that bromocrip-
tine enhanced the processing of pleasant stimuli and
haloperidol decreased the processing of pleasant stimuli.
Based on the literature, the hypotheses for unpleasant
stimuli could be less clearly formulated. Because some
studies show that dopamine only signals stimuli associated
with reward while others do find that dopamine also signals
punishment-related stimuli, we expected that bromocriptine
decreased the processing of unpleasant stimuli and halo-
peridol enhanced the processing of unpleasant stimuli.
Neutral stimuli served as control conditions.
Materials and methods
Subjects and procedure
A randomized, double-blind, placebo-controlled crossover
design was employed. Participants were 32 healthy right-
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handed male undergraduate psychology students and were
recruited by advertisement at the university campus. All
participants were non-smokers. Eleven participants could
not be included in the analysis because of excessive
electroencephalographic (EEG) artifacts in one of the three
sessions (n=3), drop out because of side effects (nausea) in
the bromocriptine treatment (n=6), or drop out because of
side effects (low blood pressure, n=1 and nausea, n=1) in
the placebo treatment. In total, 21 participants completed all
three the measurement sessions, and all analyses were
conducted using this sample. The mean age of the subjects
was 19.8 years (SD=1.2, range=18–22).
Two weeks before the experiments, participants who
were willing to participate were informed about the
procedure. One week before the start of the experiments,
subjects underwent a clinical psychiatric and physical
examination by an experienced psychiatrist (L.P.). Eligible
participants were instructed to take the medication at 8:00 A.
M., 10:00 A.M., or 12:00 A.M. 4 h before each session in the
laboratory. Further, they were instructed to abstain from
coffee, grapefruit, alcohol, and drugs at the days of the
experiment. In addition, they were instructed to abstain
from alcohol and drugs the day before the experiment. The
time between each session was always 1 week. All
participants received a financial compensation of 50 euro.
This study was approved by the Medical Ethics Committee
of the Erasmus Medical Centre, Rotterdam.
Treatment
All subjects received a single oral dose of placebo (lactose),
bromocriptine (2.5 mg), and haloperidol (2 mg) in a
counterbalanced order. The medication was provided by
the pharmacy of the Erasmus Medical Centre in indistin-
guishable capsules. It has been demonstrated that a 2-mg
dose of haloperidol does not produce serious side effects in
healthy subjects (Franken et al. 2004; Kahkonen et al.
2001). Further, 2.5 mg of bromocriptine has been shown to
modulate cognitive processes and in absence of side effects.
Based on the literature, it was not expected that the 2.5 mg
of bromocriptine would result in serious side effects (Jarvik
et al. 2000). However, after several sessions, we noticed
nausea occurring in some sessions. Because we excluded
all participants with nausea (with reference to the possible
interaction between nausea and the viewing of affective
pictures), this resulted in relatively high dropout rates. After
inclusion of 15 participants, all participants in all sessions
were provided with domperidone (10 mg) to prevent
nausea. Participants were instructed to take the domper-
idone together with the research medication1.
Stimuli and task
Before the first session, participants were instructed, and
they signed informed consent. Subsequently, participants
filled out the Positive and Negative Affect Scales (PANAS)
questionnaire and two single-item self-rating scales that
were used to assess the subjective effects of the medication
(see “Questionnaires” section). After this, the participants
were seated on a comfortable chair in a light and sound-
attenuated room. Stimuli were presented on a 21″-monitor
1.5 m away from the eyes. After attaching the electrodes
(approximately 15 min), they were instructed to pay close
attention to the pictures that would be presented. To be sure
that they paid attention to the pictures, they were told that
questions about the pictures would be asked after the
experiment.
All pictures were taken from the International Affective
Picture System (IAPS; Lang et al. 1999). To reduce test–
retest recognition effects, three pictures sets which were
closely matched on valence and arousal ratings were used
in a counterbalanced order (see Table 1). A one-way
analysis of variance (ANOVA) confirmed that there were
no differences in arousal and valence ratings between the
three sets. Further, a repeated measures ANOVA confirmed
that there were significant valence rating differences
between the three affective categories, F(2,118)=1324.2;
p<0.001. As expected, valence ratings for pleasant stimuli
were higher than for neutral stimuli, and for neutral stimuli
higher than unpleasant stimuli (higher scores indexes more
pleasantness). In addition, analysis of the arousal ratings
showed also significant differences between the three
affective categories, F(2,118)=304.5; p<0.001. Both pleas-
ant and unpleasant pictures had higher arousal ratings than
1 We did not observe any statistical significant difference between the
domperidone- and non-domperidone-receiving groups on any physi-
ological (neutral, pleasant and unpleasant EPN and LPP) or self-
reported measures (medication effects and affect).
Table 1 Mean (SD) valence and arousal ratings of the three sets of
IAPS pictures according to the normative ratings of the IAPS database
(Lang et al. 1999)
Set 1 Set 2 Set 3 Differences
between sets
(F values, ns)
Neutral valence 4.9 (0.3) 4.9 (0.4) 4.9 (0.2) 0.01
Arousal 2.7 (0.4) 2.8 (0.5) 2.7 (0.6) 0.16
Pleasant valence 7.2 (0.6) 7.2 (0.6) 7.2 (0.6) 0.06
Arousal 6.3 (0.9) 6.5 (0.7) 6.2 (1.1) 0.58
Unpleasant valence 2.5 (0.6) 2.6 (0.5) 2.6 (0.7) 0.05
Arousal 5.8 (1.0) 5.6 (0.9) 5.7 (0.9) 0.11
ns Not significant
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neutral pictures. In addition, pleasant stimuli had slightly
higher arousal ratings as compared to the unpleasant
stimuli. The neutral pictures consisted mainly of buildings,
household objects, and neutral persons. The pleasant
pictures consisted mainly of erotic and romantic scenes,
while the unpleasant pictures consisted mainly of mutilated
bodies and threat scenes.
Questionnaires
The PANAS (Watson et al. 1988) were administered as a
measure of positive and negative affect. The PANAS is a
20-item bidimensional mood inventory. Positive affect
reflects the extent to which a person feels enthusiastic,
active, and alert (Watson et al. 1988). Negative affect is a
general dimension of subjective distress and unpleasurable
engagement that subsumes a variety of aversive mood
states including anger, contempt, disgust, guilt, fear, and
nervousness (Watson et al. 1988). Psychometric properties
of the PANAS scales are good (Boon and Peeters 1999;
Watson et al. 1988).
Two single-item self-rating scales were used to assess
the subjective effects of the medication. A five-point Likert
scale (1=no effect, 5=a very strong effect) was used to
assess the magnitude of the effect. A visual analogue scale
(0=very unpleasant, 100=very pleasant) was used to assess
the pleasantness of the effect.
Electroencephalographic recording
The electrophysiological signals were recorded through the
Active-Two amplifier system (Biosemi, Amsterdam, The
Netherlands) from 64 scalp electrodes (10–20 system) using
Ag/AgCl electrodes mounted in an elastic cap. Further-
more, six additional electrodes were attached to left and
right mastoids, two outer canthi of both eyes (HEOG),
infraorbital, and supraorbital regions of the eye (VEOG).
Two additional scalp electrodes were used as reference and
ground electrodes, respectively. Online signals were
recorded from DC to 134 Hz. All signals were digitized
with a sample rate of 512 Hz and 24-bit A/D conversion.
Data were off-line re-referenced to an average reference. Off-
line, EEG and EOG activity was filtered with a bandpass of
0.05–30 Hz (phase shift-free Butterworth filters; 24 dB/
octave slope). After ocular correction (Gratton et al. 1983),
epochs including an EEG signal exceeding ±75 μV were not
included in the average. The mean 200-ms pre-stimulus
period served as baseline. After baseline correction, average
ERP waves were calculated for artifact-free trials at each
scalp site across the three stimulus conditions and across the
three treatment conditions. Brainvision Analyzer (Brain
Products, München, Germany) software was used for all
EEG analyses.
Data analysis
Definitions of the peaks of interest were based on previous
studies using the same IAPS paradigm (Franken et al. 2007;
Schupp et al. 2000, 2003a). Inspection of voltage maps of
the difference waves (emotional–neutral) revealed that the
EPN was maximal present at the following posterior sites:
P5/6, P7/8, P9/10, PO3/4, PO7/8, and O1/2 (see Fig. 1).
This site is comparable to that used by previous studies
(Franken et al. 2007; Schupp et al. 2003b). To reduce the
Fig. 1 Scalp topography of the EPN component (mean value in the
150- to 300-ms time window). Voltages represent difference scores:
Pleasant–neutral (left panel) and unpleasant–neutral (right panel).
Note that the anterior activity is positive and posterior activity is
negative
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number of covarying variables and to reduce the possible
influence of single spurious electrodes, these individual
sites were collapsed by averaging the electrodes into one
region per hemisphere (Dien and Santuzzi 2005; Schupp
et al. 2003b).2 The EPN in this area was defined as the
mean value of ERP activities in 150- to 300-ms time
windows. Note that the EPN can have positive values: The
EPN is a negative going potential showing reduced
positivity for emotional stimuli.
Inspection of voltage maps of the difference waves
(emotional–neutral) revealed that the LPP was maximal at
central and centro-parietal sites C5/6, C3/4, C1/2, CP5/6,
CP3/4, CP1/2, P5/6, P3/4, P1/2 (see Fig. 2). Again, these
individual sites were collapsed by averaging these electrodes
into one region per hemisphere. The LPP was defined as
mean value of ERP response within 400–700 ms. The LPP is
a positive deflection in the EEG, and emotional stimuli
increase the amplitude of this component. In addition,
because in previous studies valence effects on the LPP have
shown hemispheric differences (e.g., Keil et al. 2001), we
exploratively included hemisphere as factor in all ANOVAs.
Statistical analysis
To test the influence of dopaminergic manipulation on the
EPN and LPP components, a 3 (medication: placebo,
bromocriptine, haloperidol) × 3 (stimulus category: neutral,
pleasant, unpleasant) × 2 (hemisphere: left, right) repeated
measures ANOVA was employed with all variables as
within-subjects factors. For the manipulation check, a
three-way repeated measures ANOVA was used for each
self-reported measure (pleasantness and magnitude of
medication effect, positive and negative affect). In all
instances, Greenhouse–Geisser adjusted p values were used.
In case of a significant ANOVA result, partial Eta squared
(η2) as measure of effect-size is reported. Significant
ANOVA effects were followed up by pairwise comparisons
with Bonferroni adjustment.
Results
Self-reported effects
There was no significant effect of treatment on the
magnitude of the subjective effects of the medication,
F(2,40)=0.8; p=0.45. In addition, no differences in
experienced pleasantness of the medication between the
conditions was observed F(2,40)=0.0; p=0.96. Further, no
effects of the medication condition on negative, F(2,40)=
0.8; p=0.45, nor positive, F(2,40)=0.4; p=0.66, affect was
observed. Summarized, no self-reported effects of medica-
tion on magnitude and pleasantness of effects and affect
were observed.
ERP data
EPN component
Table 2 displays all mean values of the EPN and LPP
components, including standard deviations. Figs. 3, 4, 5,2 Analysis of individual electrodes resulted in similar results.
Fig. 2 Scalp topography of the LPP component (mean value in the
400- to 700-ms time window). Voltages represent difference scores:
Pleasant–neutral (left panel) and unpleasant–neutral (right panel).
Note that the anterior and posterior activities are negative and that the
central activity is positive
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and 6 show the difference ERP waves (emotional minus
neutral) for affective stimuli at the left and right hemisphere
sites. As expected, a significant main effect for stimulus
category was observed, F(2, 40)=81.0, p<0.001, η2=0.80.
Pairwise follow-up analysis show that both pleasant (p<
0.001) and unpleasant stimuli (p<0.001) yielded smaller
ERP values as compared to neutral stimuli, suggesting an
enhanced early perceptual encoding of affective stimuli.
However, no significant medication × stimulus category
interaction effect was observed F(4, 80)=0.17, ns, suggest-
ing that dopaminergic medication had no influence on this
early stage of picture processing. In addition, no other
significant main or interaction effects were observed.
LPP component
Again, a significant main effect for stimulus category was
observed, F(2, 40)=48.1, p<0.001, η2=0.71. Pairwise
follow-up analysis show that both pleasant (p<0.001) and
unpleasant stimuli (p<0.001) yielded a larger LPP compo-
nent as compared to neutral stimuli, suggesting an enhanced
processing for affective stimuli in the late elaborative phase.
In addition, a small but significant main effect of medication
was found, F(2, 40)=5.2, p<0.05, η2=0.21. Follow-up
analysis indicated that bromocriptine resulted in overall
reduced LPP waves as compared to the placebo treatment
(p<0.05), suggesting that bromocriptine results in an overall
reduced processing of pictorial stimuli in this stage. Further,
a small but significant stimulus-category × hemisphere
interaction effect was observed, F(2, 40)=3.7, p<0.05, η2=
0.16. Because none of the post hoc tests resulted in a
significant pairwise comparison, and this interaction had not
our major interest, we will not discuss this finding in further
detail. Most important for our hypothesis, no significant
stimulus category × medication interaction effect was found,
suggesting that the employed dopamine antagonist and
agonist had no selective influence on affective processing.
Discussion
To our knowledge, this is the first study examining the
influence of dopamine on ERP correlates of affective
stimulus processing. The present study demonstrates that
an acute low dose of bromocriptine resulted in globally
Table 2 Mean (SD) values of the EPN and LPP components in left
and right hemisphere towards neutral, pleasant, and unpleasant
pictures for the placebo, bromocriptine, and haloperidol treatment
conditions (n=21)
Placebo Bromocriptine Haloperidol
EPN neutral left 9.4 (3.6) 8.4 (3.7) 9.4 (4.4)
Right 8.6 (3.1) 8.5 (4.2) 8.9 (3.6)
EPN pleasant left 7.0 (4.3) 6.0 (4.0) 6.9 (4.2)
Right 6.7 (3.8) 6.3 (4.5) 6.8 (3.8)
EPN unpleasant left 8.6 (4.0) 8.0 (3.8) 8.6 (4.4)
Right 8.5 (4.0) 8.2 (4.4) 8.6 (4.3)
LPP neutral left 3.5 (1.6) 3.2 (1.9) 3.4 (1.8)
Right 3.8 (1.4) 3.1 (1.7) 3.3 (1.7)
LPP pleasant left 4.9 (1.9) 4.6 (1.8) 4.8 (2.1)
Right 4.6 (2.0) 4.2 (1.8) 4.2 (1.7)
LPP unpleasant left 5.4 (1.7) 4.7 (1.7) 5.5 (2.0)
Right 4.8 (1.9) 4.2 (1.8) 4.5 (1.9)
Fig. 3 Differences waves
(pleasant–neutral) for pleasant
stimuli at the left and right
posterior cluster (P5/6, P7/8, P9/
10, PO3/4, PO7/8, and O1/2) for
placebo (black line), bromocrip-
tine (gray line), and haloperidol
(dotted line) treatment condi-
tions separately
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reduced LPP waves as compared to the placebo treatment,
suggesting that bromocriptine results in decreased cortical
processing of pictorial information. Although there are no
previous studies using an acute low dose of bromocriptine
examining the processing of emotional pictures (as in the
present study), these results are in line with a study of
Oranje et al. (2004). Although in that study a different
paradigm was employed and different components were
studied, these authors found a globally reduced ERP
response as result of bromocriptine treatment. In contrast
to bromocriptine, an acute low dose haloperidol did not
result in a non-specific modification of cortical processing
of pictorial information. Previous studies addressing infor-
mation processing using haloperidol and ERP measures
yielded mixed results. For example, Kahkonen et al. (2001)
did observe a global reduction of ERP waves using 2 mg
(oral) of haloperidol. In contrast, other studies did not
observe a general effect of haloperidol on ERP amplitudes
Fig. 4 Differences waves
(unpleasant–neutral) for un-
pleasant stimuli at the left and
right posterior cluster (P5/6, P7/
8, P9/10, PO3/4, PO7/8, and
O1/2) for placebo (black line),
bromocriptine (gray line), and
haloperidol (dotted line) treat-
ment conditions separately
Fig. 5 Differences waves
(pleasant–neutral) for pleasant
stimuli at the left and right
central/centro-parietal clusters
(C5/6, C3/4, C1/2, CP5/6, CP3/
4, CP1/2, P5/6, P3/4, P1/2) for
placebo (black line), bromocrip-
tine (gray line), and haloperidol
(dotted line) treatment condi-
tions separately
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(e.g. Ford et al. 1994). Clearly, the effects of haloperidol on
ERPs are dependent on dose, ERP component, characteristics
of the participants, and experimental paradigms that are used.
Most importantly, we could not confirm the hypothesis
that D2 receptor modulation results in a modulation of
cortical processing of affective stimuli. Neither an acute
low dose of bromocriptine nor an acute low dose of
haloperidol did differentially modulate the brain’s electro-
physiological response towards affective stimuli. This
finding suggests that dopamine D2 receptors are not
involved in the cortical processing of affective information.
Because the studied ERP components measured in the
present study are associated with attentive motivational
processing (Schupp et al. 2006, 2007), it can be concluded
that motivational attentive processing is not affected by
haloperidol nor bromocriptine. Given that the ERPs in the
present study reflect attentive processing, the results are in
line with Oranje et al. (2006) who did not find any effects
of L-dopa nor bromocriptine on ERP indices of selective
attention in healthy volunteers.
In addition to the main finding that modulation of the D2
receptor did not result in early (EPN) or late (LPP) effect on
ERPs indexing early perceptual encoding of emotional
material and subsequent elaborative processing, we did not
observe an effect of haloperidol and bromocriptine on the
subjective self-reported affect. Neither medication had an
effect on positive or negative affect. However, it must be
noted that the present study was not specifically designed to
measure the subjective effects of the medication. In
addition, although the present results show that dopamine
is not associated with the perception of reward-associated
stimuli per se, it still might be associated with establishing
stimulus–reward associations or functions dealing with
reward-related motor responses. In addition, it might be
that the reward processing is only modulated by dopami-
nergic agents in persons with a genetically heightened
reward sensitivity, for example, carriers of the A1 allele of
the dopamine D2 TaqIA gene (Kirsch et al. 2006).
The present study suggests that low doses of bromocrip-
tine in Parkinson’s disease patients and haloperidol in
schizophrenia patients may have limited influence on
affective processing and self-reported affect in patients
having these disorders. However, it must be noted that we
did only study the effects of an acute dose of these
medications; it is not known whether these effects differ
from those associated with long term use of medication.
The present study has several limitations. First, there was
a substantial dropout in the bromocriptine treatment. It may
be that this is a specific subgroup of persons with heightened
sensitivity for dopamine agonists. Because this group is not
included in the analysis, this might have resulted in lowered
generalizability of the results. Second, because of risks of
unwanted side effects, we employed rather low doses of
bromocriptine and haloperidol, 2 mg and 2.5 mg, respec-
tively. Third, a possible limitation of this study is that some
participants received domperidone and others did not, which
may have influenced the results. However, it must be noted
that domperidone does not cross the blood–brain barrier but
exerts its effect peripherally, and as such, does not have a
major influence on the central dopamine system (Barone
Fig. 6 Differences waves
(unpleasant–neutral) for un-
pleasant stimuli at the left and
right central clusters (C5/6, C3/
4, C1/2, CP5/6, CP3/4, CP1/2,
P5/6, P3/4, P1/2) for placebo
(black line), bromocriptine (gray
line), and haloperidol (dotted
line) treatment conditions
separately
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1999; Champion et al. 1986). In addition, additional
statistical analyses show that domperidone did not influence
any of the outcome variables (electrophysiological nor self-
reported) used in the present study.
Summarizing, the present results indicate that neither an
acute low dose of bromocriptine nor an acute low dose of
haloperidol has selective effect on electrophysiological
indices of affective processing and self-reported affect. In
contrast, bromocriptine decreased overall processing of all
stimulus categories regardless of their affective content.
The results indicate that dopaminergic D2 receptors do not
seem to play a crucial role in the selective processing of
affective visual stimuli.
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